Conformation-specific anti-von Willebrand factor antibodies
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsRobert I. Handin, Huabing Yuan, Anne McLeod
Life of this patent
Estimating the term…
Abstract
The present invention is directed to antibodies and antibody fragments that bind specifically to the active conformation of human von Willebrand factor. Most preferred are recombinantly produced single chain variable immunoglobulin fragments. Because the antibodies or antibody fragments act only at the sites of thrombus formation and do not interfere with the normal activity of circulating platelets, they are particularly well suited for use as antithrombotic agents in a wide variety of applications.
Claims6
A method of inhibiting the binding of human vWF to platelets, comprising contacting said human vWF with a single chain variable region immunoglobulin (ScFv) fragment that binds to the active conformation of human vWF with at least a hundredfold greater affinity than to unactivated vWF and that inhibits the binding of vWF to platelets, wherein said ScFv fragment is produced by a method comprising:
- (a) immunizing an animal with an immunogen derived from the A1 region of human vWF;
- (b) isolating mRNA from the immunized animal of step (a);
- (c) producing a cDNA library from the isolated mRNA of step (b) in a bacteriophage capable of displaying ScFv fragments encoded by cloned cDNA;
- and
- (d) screening the library of step (c) to identify a bacteriophage displaying a ScFv fragment that binds selectively to the active conformation of vWF.
A method of inhibiting the binding of human vWF to platelets, comprising contacting said human vWF with a single chain variable region immunoglobulin (ScFv) fragment that binds to the active conformation of human vWF with at least a hundredfold greater affinity than to unactivated vWF and that inhibits the binding of vWF to platelets, wherein said ScFv fragment is produced by a method comprising:
- (a) immunizing an animal with an immunogen derived from the A1 region of human vWF;
- (b) isolating mRNA from the immunized animal of step (a);
- (c) producing a cDNA library from the isolated mRNA of step (b) in a bacteriophage capable of displaying ScFv fragments encoded by cloned cDNA;
- (d) screening the library of step (c) to identify a bacteriophage displaying a ScFv fragment that binds selectively to the active conformation of vWF;
- (e) subcloning the recombinant DNA encoding the ScFv fragment identified in step (d) in an expression vector;
- (f) transforming a host cell capable of expressing recombinant ScFv with the expression vector of step (e);
- and
- (g) purifying the recombinant ScFv fragment produced by the host cell of step (f).
A method of inhibiting the binding of human vWF to platelets, comprising contacting said human vWF with a single chain variable region immunoglobulin (ScFv) fragment that binds to the active conformation of human vWF with at least a hundredfold greater affinity than to unactivated vWF and that inhibits the binding of vWF to platelets.
A method of preventing thrombus formation in a patient, comprising administering to said patient a pharmaceutical composition comprising a single chain variable region immunoglobulin (ScFv) fragment that binds to the active conformation of human vWF with at least a hundredfold greater affinity than to unactivated vWF and that inhibits the binding of vWF to platelets, wherein said ScFv fragment is produced by a method comprising:
- (a) immunizing an animal with an immunogen derived from the A1 region of human vWF;
- (b) isolating mRNA from the immunized animal of step (a);
- (c) producing a cDNA library from the isolated mRNA of step (b) in a bacteriophage capable of displaying ScFv fragments encoded by cloned cDNA;
- (d) screening the library of step (c) to identify a bacteriophage displaying a ScFv fragment that binds selectively to the active conformation of vWF;
- and
- wherein said pharmaceutical composition is administered at a dosage sufficient to inhibit said thrombus formation.
A method of preventing thrombus formation in a patient, comprising administering to said patient a pharmaceutical composition comprising a single chain variable region immunoglobulin (ScFv) fragment that binds to the active conformation of human vWF with at least a hundredfold greater affinity than to unactivated vWF and that inhibits the binding of vWF to platelets, wherein said ScFv fragment is produced by a method comprising:
- (a) immunizing an animal with an immunogen derived from the A1 region of human vWF;
- (b) isolating mRNA from the immunized animal of step (a);
- (c) producing a cDNA library from the isolated mRNA of step (b) in a bacteriophage capable of displaying ScFv fragments encoded by cloned cDNA;
- (d) screening the library of step (c) to identify a bacteriophage displaying a ScFv fragment that binds selectively to the active conformation of vWF;
- (e) subcloning the recombinant DNA encoding the ScFv fragment identified in step (d) in an expression vector;
- (f) transforming a host cell capable of expressing recombinant ScFv with the expression vector of step (e);
- (g) purifying the recombinant ScFv fragment produced by the host cell of step (f);
- and
- wherein said pharmaceutical composition is administered at a dosage sufficient to inhibit said thrombus formation.
A method of preventing thrombus formation in a patient comprising administering to said patient a pharmaceutical composition comprising a single chain variable region immunoglobulin (ScFv) fragment that binds to the active conformation of human vWF with at least a hundredfold greater affinity than to unactivated vWF and that inhibits the binding of vWF to platelets, and wherein said pharmaceutical composition is administered at a dosage sufficient to inhibit said thrombus formation.
Dependencies are inferred from the claim text.